OppenheimerFunds’s Acadia Pharmaceuticals ACAD Stock Holding History

OppenheimerFunds’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$97.9M	Buy	3,644,406 +15,830	+0.4%	+$370K	0.12%	173
2018 Q4	$58.7M	Sell	3,628,576 -85,390	-2%	-$1.66M	0.08%	240
2018 Q3	$77.1M	Sell	3,713,966 -744,410	-17%	-$11.7M	0.09%	245
2018 Q2	$68.1M	Buy	4,458,376 +112,430	+3%	+$2M	0.08%	268
2018 Q1	$97.7M	Sell	4,345,946 -467,153	-10%	-$12.9M	0.12%	186
2017 Q4	$145M	Sell	4,813,099 -325,374	-6%	-$10.4M	0.18%	145
2017 Q3	$194M	Buy	5,138,473 +63,873	+1%	+$2.08M	0.24%	112
2017 Q2	$142M	Buy	5,074,600 +156,314	+3%	+$4.66M	0.17%	150
2017 Q1	$169M	Buy	4,918,286 +170,289	+4%	+$6.01M	0.2%	132
2016 Q4	$137M	Sell	4,747,997 -402,226	-8%	-$10.6M	0.17%	148
2016 Q3	$164M	Buy	5,150,223 +158,572	+3%	+$5.38M	0.21%	131
2016 Q2	$162M	Buy	4,991,651 +359,960	+8%	+$12M	0.21%	125
2016 Q1	$130M	Buy	4,631,691 +703,256	+18%	+$15.3M	0.17%	146
2015 Q4	$140M	Buy	3,928,435 +211,963	+6%	+$7.47M	0.18%	136
2015 Q3	$123M	Sell	3,716,472 -63,326	-2%	-$2.63M	0.17%	156
2015 Q2	$158M	Buy	3,779,798 +70,291	+2%	+$2.72M	0.18%	145
2015 Q1	$121M	Buy	+3,709,507	New	+$128M	0.14%	192

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

OppenheimerFunds's ACAD Position: Q1 2019 in Review

OppenheimerFunds increased its Acadia Pharmaceuticals (ACAD) stake by 0.44% in Q1 2019, buying an estimated $370K and bringing the position to 3,644,406 shares worth $97.9M. The position accounts for 0.12% of the portfolio, ranked #173.

OppenheimerFunds first reported a position in ACAD in Q1 2015 and has held it in 17 quarters since. The position peaked at $194M in Q3 2017. 199 funds tracked by Wall St. Rank hold ACAD as of Q1 2019.

OppenheimerFunds held 3,644,406 shares of Acadia Pharmaceuticals worth $97.9M as of Q1 2019.
OppenheimerFunds bought 15,830 Acadia Pharmaceuticals shares in Q1 2019, an estimated $370K.
Acadia Pharmaceuticals made up 0.12% of OppenheimerFunds's portfolio in Q1 2019, its #173 holding.
OppenheimerFunds first reported a position in Acadia Pharmaceuticals in Q1 2015 and has held it in 17 quarters since.
OppenheimerFunds's Acadia Pharmaceuticals position peaked at $194M in Q3 2017.
199 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.